Aeras Global TB Vaccine Foundation, Rockville, Maryland 20850, USA.
Clin Infect Dis. 2010 May 15;50 Suppl 3:S178-83. doi: 10.1086/651489.
Current tuberculosis (TB)-control methods, which do not include an adequate vaccine, do not effectively block transmission of TB. Modeling studies show that mass vaccination campaigns using new vaccines could prevent 85.9 million new cases and 14.5 million deaths from 2015 through 2050 in southern Asia alone. After a dearth of many years, the development pipeline now includes 7 vaccine candidates that are being tested in humans. Two nonreplicating viral vectored vaccines have very recently entered the first phase IIb efficacy trial in infants (the first such trial in 80 years) and in human immunodeficiency virus-infected adults. Science is moving forward, but the scientific advancements need to be accompanied by political mobilization to ensure that the resources are available to develop, manufacture, and distribute the new vaccines and, thus, save millions of lives.
目前的结核病（TB）控制方法不包括有效的疫苗，不能有效阻断结核病的传播。建模研究表明，仅在南亚地区，使用新疫苗开展大规模疫苗接种活动，可预防 2015 年至 2050 年期间的 8590 万例新发病例和 1450 万人死亡。在沉寂多年后，目前的疫苗研发管道包括 7 种正在进行人体测试的候选疫苗。两种非复制型病毒载体疫苗最近刚刚进入婴儿（80 年来首次开展此类试验）和人类免疫缺陷病毒感染成人的 IIb 期疗效试验。科学正在向前发展，但科学进步需要辅以政治动员，以确保有资源开发、生产和分发新疫苗，从而拯救数百万人的生命。
